Dr. Kaimakliotis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1701 N Senate Ave
Indianapolis, IN 46202Phone+1 317-948-6351Fax+1 317-944-0174
Education & Training
Yale-New Haven Medical CenterResidency, Urology, 2008 - 2012
Yale School of MedicineClass of 2007
Certifications & Licensure
IN State Medical License 2013 - 2025
CT State Medical License 2012 - 2013- American Board of Urology Urology
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- 7 citationsLiquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction.Yu Yang, Catherine R. Miller, Antonio Lopez-Beltran, Rodolfo Montironi, Monica Cheng
Critical Reviews in Oncogenesis. 2017-01-01 - 29 citationsPatients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.Yair Lotan, Joep J. de Jong, Vinnie Y. T. Liu, Tarek A. Bismar, Stephen A. Boorjian
The Journal of Urology. 2021-10-13 - 90 citationsStaging of Bladder CancerMartin J. Magers, Antonio Lopez-Beltran, Rodolfo Montironi, Sean R. Williamson, Hristos Z. Kaimakliotis
Histopathology. 2019-01-01
Authored Content
- Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
